Program
venetoclax
Also written as “Venetoclax”, “ABT-199” and “ABT-199 (Main Cohort)”.
Its studies are mostly in Leukemia, Myeloid, Acute · Leukemia, Lymphocytic, Chronic, B-Cell · Multiple Myeloma · Lymphoma, Non-Hodgkin · Lymphoma, Mantle-Cell, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 5312 open or running | phase 4since Nov 22, 2021 | Apr 1, 2011 | Nov 2026phase 2 · NCT04895436 |
| Hoffmann-La Roche | 131 open or running | phase 3since Dec 4, 2013 | Aug 10, 2012 | none ahead |
| Oncotherapeutics | 11 open or running | phase 2since Aug 11, 2023 | Aug 11, 2023 | none ahead |
Also a collaborator on its studies: Johnson & Johnson, baili-bio-chengdu-pharmaceutical-co-ltd, roche-genentech, Merck, Sumitomo Pharma and Bristol-Myers Squibb.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Oct 12, 2012.
- Jun 5, 2020Phase 1 study in Small Cell Lung CarcinomaHoffmann-La Roche · NCT04422210 · 2 enrolled · United States, Denmark, Korea, Republic of and more
- Jul 17, 2020Phase 2 study in Lymphoma, Mantle-CellAbbVie · NCT04477486 · 13 enrolled · Japan
- Aug 10, 2020Phase 3 study in Leukemia, Myeloid, AcuteAbbVie · NCT04509622 · 14 enrolled · Japan
- Mar 8, 2021Phase 1 study in Lymphoma, Large B-Cell, DiffuseHoffmann-La Roche · NCT04790903 · 50 enrolled · United States, France, Italy and more
- Mar 19, 2021Phase 1 study in Renal InsufficiencyAbbVie · NCT04810598 · 12 enrolled · United States
- May 19, 2021Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellAbbVie · NCT04895436 · 75 planned · United States, Australia, Austria and more
- Nov 22, 2021Phase 4 study in Leukemia, Myeloid, AcuteAbbVie · NCT05144243 · 44 enrolled · China
- Jun 12, 2023Phase 1 study in Healthy VolunteersAbbVie · NCT05909553 · 15 enrolled · United States
- Aug 11, 2023Oncotherapeutics's first study: phase 2 study in Multiple MyelomaNew to OncotherapeuticsOncotherapeutics · NCT06115135 · 39 planned · United States
- Oct 2, 2023Phase 1 study in Healthy VolunteersAbbVie · NCT06070948 · United States
- Jul 23, 2024Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellHoffmann-La Roche · NCT06524375 · 118 enrolled · United States
- Dec 17, 2024Phase 1 study in Healthy VolunteerAbbVie · NCT06742086 · 72 enrolled · United States
- Jun 23, 2025Phase 4 study in Leukemia, Myeloid, AcuteAbbVie · NCT07044687 · 100 planned · India
- Jan 28, 2026Phase 2 study in Waldenstrom MacroglobulinemiaAbbVie · NCT07387471 · 14 enrolled · Japan
Ahead
- Nov 2026Primary completion: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellAbbVie · NCT04895436
- Jun 2027Primary completion: phase 2 study in Multiple MyelomaAbbVie · NCT02899052
- Jul 2027Primary completion: phase 3 study in Myelodysplastic SyndromesAbbVie · NCT04401748
- Aug 2027Primary completion: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellAbbVie · NCT03844048
TargetBeta
“Apoptosis regulator Bcl-2 inhibitor”ChEMBL 37, by rule
Other programs on BCL2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Bcl-2 Inhibitor TQB3909 | Sino Biopharmaceutical | phase 3 | 8 |
| lacutoclaxrule | Lupeng Pharmaceutical | phase 2 | 4 |
| surzetoclax | AbbVie | phase 2 | 3 |
| 400mg of TQB3909 tablets | Sino Biopharmaceutical | phase 2 | 1 |
| surzetoclax | AbbVie | phase 1 | 2 |
| FXS0683 | Fosun Pharma | phase 1 | 1 |
Studies
The newest 60 of 67 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07387471Waldenstrom Macroglobulinemia · Japan | 2 | Active, not recruiting | AbbVie | Jul 2028 | 14 |
| NCT07044687Leukemia, Myeloid, Acute · India | 4 | Recruiting | AbbVie | Nov 2027 | 100 |
| NCT06742086Healthy Volunteer · United States | 1 | Completed | AbbVie | Oct 8, 2025 | 72 |
| NCT06524375Leukemia, Lymphocytic, Chronic, B-Cell · United States | 2 | Active, not recruiting | Hoffmann-La Roche | Oct 28, 2026 | 118 |
| NCT06070948Healthy Volunteers · United States | 1 | Withdrawn | AbbVie | Jul 28, 2025 | 0 |
| NCT06115135Multiple Myeloma · United States | 2 | Recruiting | Oncotherapeutics | Apr 30, 2026 | 39 |
| NCT05909553Healthy Volunteers · United States | 1 | Completed | AbbVie | Sep 22, 2023 | 15 |
| NCT05144243Leukemia, Myeloid, Acute · China | 4 | Active, not recruiting | AbbVie | Mar 2026 | 44 |
| NCT04895436Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 2 | Recruiting | AbbVie | Nov 2026 | 75 |
| NCT04810598Renal Insufficiency · United States | 1 | Completed | AbbVie | Aug 16, 2022 | 12 |
| NCT04790903Lymphoma, Large B-Cell, Diffuse · United States, France, Italy and more | 1 | Terminated | Hoffmann-La Roche | May 21, 2024 | 50 |
| NCT04509622Leukemia, Myeloid, Acute · Japan | 3 | Completed | AbbVie | Apr 15, 2021 | 14 |
| NCT04477486Lymphoma, Mantle-Cell · Japan | 2 | Completed | AbbVie | Feb 9, 2022 | 13 |
| NCT04422210Small Cell Lung Carcinoma · United States, Denmark, Korea, Republic of and more | 1 | Terminated | Hoffmann-La Roche | Nov 6, 2020 | 2 |
| NCT04401748Myelodysplastic Syndromes · United States, Australia, Austria and more | 3 | Active, not recruiting | AbbVie | Jul 2027 | 531 |
| NCT04298918Breast Neoplasms · Australia, Korea, Republic of | 2 | Terminated | Hoffmann-La Roche | Feb 4, 2021 | 1 |
| NCT04285567Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, France and more | 3 | Completed | Hoffmann-La Roche | Mar 19, 2024 | 166 |
| NCT04274933Breast Neoplasms · United States, Germany, Japan and more | 1 | Terminated | AbbVie | Oct 8, 2020 | 4 |
| NCT04274907Carcinoma, Non-Small-Cell Lung · United States | 1 | Terminated | AbbVie | Feb 2, 2021 | 2 |
| NCT04161885Leukemia, Myeloid, Acute · United States, Australia, Brazil and more | 3 | Terminated | AbbVie | Sep 23, 2025 | 465 |
| NCT04102020Leukemia, Myeloid, Acute · United States, Australia, Canada and more | 3 | Completed | AbbVie | Sep 29, 2022 | 112 |
| NCT03873493Leukemia · United States, Australia, Austria and more | 2 | Completed | AbbVie | Nov 4, 2021 | 14 |
| NCT03844048Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 3 | Active, not recruiting | AbbVie | Aug 2027 | 165 |
| NCT03785184Multiple Myeloma · United States, Australia, Canada and more | 2 | Withdrawn | AbbVie | Aug 22, 2019 | 0 |
| NCT03584009Breast Neoplasms · United States, Australia, Canada and more | 2 | Terminated | Hoffmann-La Roche | Aug 5, 2020 | 103 |
| NCT03567616Multiple Myeloma · United States, Spain, United Kingdom | 2 | Terminated | AbbVie | Jun 18, 2020 | 8 |
| NCT03557619Hematologic Neoplasms · United States, Australia | 1 | Recruiting | AbbVie | Mar 21, 2026 | 12 |
| NCT03539744Multiple Myeloma · United States, Australia, Canada and more | 3 | Active, not recruiting | AbbVie | Aug 2026 | 265 |
| NCT03484520Neoplasms · United States, Australia, Spain | 1 | Terminated | AbbVie | Dec 1, 2022 | 48 |
| NCT03441555Leukemia, Myeloid, Acute · United States, Germany, United Kingdom | 1 | Completed | AbbVie | Jan 25, 2021 | 36 |
| NCT03406156Leukemia, Lymphocytic, Chronic, B-Cell · United States | 3 | Completed | AbbVie | Oct 12, 2021 | 120 |
| NCT03312530Multiple Myeloma · Czechia, Denmark, France and more | 2 | Completed | Hoffmann-La Roche | May 18, 2021 | 49 |
| NCT03314181Multiple Myeloma · United States, Australia, Canada and more | 2 | Active, not recruiting | AbbVie | May 2031 | 156 |
| NCT03236857Neoplasms · United States, Australia, Canada and more | 1 | Completed | AbbVie | Apr 19, 2023 | 143 |
| NCT03181126Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States, Australia | 1 | Completed | AbbVie | Nov 11, 2020 | 69 |
| NCT03112174Lymphoma, Mantle-Cell · United States, Australia, Belgium and more | 3 | Completed | AbbVie | Jun 26, 2024 | 366 |
| NCT03069352Leukemia, Myeloid, Acute · United States, Argentina, Australia and more | 3 | Completed | AbbVie | Feb 15, 2019 | 211 |
| NCT02993523Leukemia, Myeloid, Acute · United States, Australia, Austria and more | 3 | Active, not recruiting | AbbVie | Dec 1, 2021 | 443 |
| NCT02980731Leukemia, Lymphocytic, Chronic, B-Cell · Argentina, Australia, Bulgaria and more | 3 | Completed | AbbVie | Dec 29, 2021 | 210 |
| NCT02966782Myelodysplastic Syndromes · United States, Australia, Germany | 1 | Completed | AbbVie | Apr 5, 2023 | 70 |
| NCT02966756Leukemia, Lymphocytic, Chronic, B-Cell · Australia, China, New Zealand and more | 2 | Active, not recruiting | AbbVie | Dec 2030 | 66 |
| NCT02942290Myelodysplastic Syndromes · United States, Australia, Canada and more | 1 | Completed | AbbVie | Apr 15, 2026 | 134 |
| NCT02910583Leukemia · United States, Australia, Italy and more | 2 | Completed | AbbVie | Nov 12, 2020 | 323 |
| NCT02899052Multiple Myeloma · United States, Australia, Hungary and more | 2 | Active, not recruiting | AbbVie | Jun 2027 | 120 |
| NCT02756611Leukemia, Lymphocytic, Chronic, B-Cell · United States, Austria, Belgium and more | 3 | Completed | AbbVie | Apr 10, 2019 | 258 |
| NCT02755597Multiple Myeloma · United States, Australia, Brazil and more | 3 | Completed | AbbVie | Mar 15, 2021 | 291 |
| NCT02287233Leukemia, Myeloid, Acute · United States, Australia, Germany and more | 2 | Completed | AbbVie | Aug 10, 2021 | 94 |
| NCT02265731Lymphoma, Non-Hodgkin · Japan | 2 | Completed | AbbVie | Mar 12, 2021 | 38 |
| NCT02242942Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more | 3 | Completed | Hoffmann-La Roche | Aug 17, 2018 | 445 |
| NCT02187861Lymphoma, Follicular · United States, Australia, Belgium and more | 2 | Completed | Hoffmann-La Roche | Sep 27, 2016 | 163 |
| NCT02141282Leukemia, Lymphocytic, Chronic, B-Cell · United States | 2 | Completed | AbbVie | Dec 22, 2021 | 127 |
| NCT02055820Lymphoma, Non-Hodgkin · United States, Australia, Austria and more | 2 | Completed | Hoffmann-La Roche | Jun 28, 2017 | 267 |
| NCT02095574Lymphoma, Non-Hodgkin | 1 | Withdrawn | AbbVie | Sep 2014 | 0 |
| NCT02005471Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 3 | Completed | Hoffmann-La Roche | May 8, 2017 | 389 |
| NCT01994837Leukemia, Myeloid, Acute | 2 | Completed | AbbVie | Dec 2014 | 32 |
| NCT01969695Lymphoma, Non-Hodgkin · United States | 1 | Completed | AbbVie | Dec 16, 2019 | 11 |
| NCT01969682Lymphoma, Non-Hodgkin · United States | 1 | Withdrawn | AbbVie | May 2014 | 0 |
| NCT01969669Lymphoma, Non-Hodgkin · United States | 1 | Completed | AbbVie | Sep 2014 | 12 |
| NCT01889186Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Canada and more | 2 | Completed | AbbVie | Oct 28, 2020 | 158 |
| NCT01794520Multiple Myeloma · United States, Belgium, France and more | 2 | Completed | AbbVie | Nov 29, 2021 | 117 |
How it is read
Names in the registry
- “Venetoclax”, 66 entries
- “ABT-199”, 9 entries
- “venetoclax”, 6 entries
- “ABT-199 (Main Cohort)”, 1 entry
- “ABT-199 (Safety Expansion Cohort)”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 21 studies
- Leukemia, Lymphocytic, Chronic, B-Cell, 21 studies
- Multiple Myeloma, 10 studies
- Lymphoma, Non-Hodgkin, 7 studies
- Lymphoma, Mantle-Cell, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.